| Literature DB >> 24904231 |
Helen E Gruber1, Wei Sha2, Cory R Brouwer2, Nury Steuerwald3, Gretchen L Hoelscher1, Edward N Hanley1.
Abstract
BACKGROUND: Disc degeneration and its associated low back pain are a major health care concern causing disability with a prominent role in this country's medical, social and economic structure. Low back pain is devastating and influences the quality of life for millions. Low back pain lifetime prevalence approximates 80% with an estimated direct cost burden of $86 billion per year. Back pain patients incur higher costs, greater health care utilization, and greater work loss than patients without back pain.Entities:
Keywords: SNP; catechol-O-methyltransferase (COMT); low back pain.
Mesh:
Substances:
Year: 2014 PMID: 24904231 PMCID: PMC4045795 DOI: 10.7150/ijms.8770
Source DB: PubMed Journal: Int J Med Sci ISSN: 1449-1907 Impact factor: 3.738
Demographic Features of Study Population by Disc Grade (% Incidence).
| Grade I (n = 1) | Grade II (n = 6) | Grade III (N = 12) | Grade IV (n = 17) | Grade V (n = 4) | ||
|---|---|---|---|---|---|---|
| ≤35 | 100% | 33.33% | 25% | 17.65% | 0 | |
| 36-59 | 0 | 66.67% | 75% | 58.82% | 50% | |
| ≥60 | 0 | 0 | 0 | 23.52% | 50% | |
| Male | 100% | 33.33% | 41.67% | 35.29% | 50% | |
| Female | 0 | 66.67% | 58.33% | 64.71% | 50% | |
| Black | 0 | 33.33% | 33.33% | 23.53% | 25% | |
| White (not of Hispanic origin) | 0 | 66.67% | 66.67% | 76.47% | 75% | |
| Unknown | 100% | 0 | 0 | 0 | 0 | |
| L2-3 | 0 | 0 | 0 | 5.88% | 0 | |
| L3-4 | 0 | 16.67% | 0 | 0 | 25% | |
| L4-5 | 0 | 33.33% | 41.67% | 35.29% | 50% | |
| L5-S1 | 100% | 50% | 58.33% | 58.82% | 25% | |
*L, lumbar; S, sacral
SNPs Significantly Associated with Disc Degeneration.
| Gene | COMT | COMT | Intergenic | Intergenic | ||||
|---|---|---|---|---|---|---|---|---|
| SNP | Rs165656 | Rs4633 | Rs2095019 | Rs4708592 | ||||
| Major allele (allele 1) | G | C | C | T | ||||
| Minor allele (allele 2) | C | T | A | C | ||||
| Association with disc degeneration previously reported in the literature | No | Yes | No | No | ||||
| Raw P-value | 0.00113 | 0.001133 | 0.000833 | 0.001281 | ||||
| P-value (after multiple testing | 0.043054 | 0.043054 | 0.031653 | 0.048662 | ||||
| Genotype Incidence (# (%)) | GG or GC | CC | CC or CT | TT | CC | CA or AA | TT | TC or CC |
| Grade I * | 1 (100%) | 0 (0%) | 1 (100%) | 0 (0%) | 0 (0%) | 1 (100%) | 0 (0%) | 1 (100%) |
| Grade II | 2 (33%) | 4 (67%) | 2 (33%) | 4 (67%) | 1 (17%) | 5 (83%) | 2 (33%) | 4 (67%) |
| Grade III | 9 (75%) | 3 (25%) | 9 (75%) | 3 (25%) | 4 (33%) | 8 (67%) | 7 (58%) | 5 (42%) |
| Grade IV | 13 (76%) | 4 (24%) | 13 (76%) | 4 (24%) | 13 (76%) | 4 (24%) | 16 (94%) | 1 (6%) |
| Grade V | 4 (100%) | 0 (0%) | 4 (100%) | 0 (0%) | 3 (75%) | 1 (25%) | 4 (100%) | 0 (0%) |
* Note the small sample size in the Grade I analysis (n=1) which was present here.